Loading…
5 companies · GEL, thousands · columns ordered by revenue
| Company | Sector | EBITDA margin · FY 2024 | Percentile | Sector n |
|---|---|---|---|---|
| Klinika Rustavi | Healthcare Services | 12.8% | 58th pct | 268 |
| Clinic-LJ | Healthcare Services | 9.1% | 48th pct | 268 |
| National Center of Tube… | Healthcare Services | -16.9% | 10th pct | 268 |
| St. Michael the Archang… | Healthcare Services | -27.5% | 6th pct | 268 |
| Infectious Pathology, A… | Healthcare Services | — | no FY data | 268 |
Percentile is within each company's own sector across the whole FY2024 cross-section (1st–100th; higher = larger value). Companies with no sector, or no filing for the year, are not ranked.
Only 4 of 5 peers filed FY2024. Switch to FY2023 (5 of 5).
| Ratio — FY 2024 | Klinika Rustavi | Clinic-LJ | National Center of Tube… | St. Michael the Archang… | Infectious Pathology, A… |
|---|---|---|---|---|---|
| Margins | |||||
| Gross Margin | 79.4% | 27.5% | 2.4% | 72.7% | — |
| EBITDA Margin | 12.8% | 9.1% | -16.9% | -27.5% | — |
| EBITDAR | 2,252 | 1,417 | -2,633 | -4,194 | — |
| EBITDAR Margin | 13.5% | 9.1% | -16.9% | -27.5% | — |
| EBIT Margin | 5.7% | 9.1% | -20.3% | -36.0% | — |
| Net Profit Margin | 4.4% | 7.2% | -18.0% | -40.0% | — |
| Operating Expense % of Sales | 66.6% | 18.4% | 19.3% | 108.8% | — |
| Returns | |||||
| Return on Assets (ROA) | 7.4% | 9.9% | -6.3% | -18.2% | — |
| Return on Equity (ROE) | 12.9% | 22.1% | -7.2% | -49.3% | — |
| ROIC [EBIT / Invested Capital] | |||||
| 12.1% |
| 16.0% |
| -8.2% |
| -24.8% |
| — |
| Leverage & debt balances | |||||
| Debt-to-Assets | 26.2% | 34.1% | 1.2% | 29.5% | — |
| Debt-to-Equity | 0.46x | 0.77x | 0.01x | 0.80x | — |
| Debt-to-EBITDA | 1.21x | 2.75x | N/A | N/A | — |
| Equity-to-Assets | 57.4% | 44.6% | 86.6% | 37.0% | — |
| Net Debt | 2,221 | 3,766 | -291 | 9,702 | — |
| Cash & Equivalents | 387 | 129 | 811 | 172 | — |
| Total Debt | 2,609 | 3,895 | 520 | 9,874 | — |
| Liquidity & working capital | |||||
| Current Ratio | 1.31x | 2.78x | 0.53x | 1.13x | — |
| Quick Ratio | 1.31x | 2.35x | 0.29x | 0.91x | — |
| Cash Ratio | 0.25x | 0.05x | 0.14x | 0.02x | — |
| Total Current Assets | 2,066 | 6,876 | 3,188 | 12,693 | — |
| Total Current Liabilities | 1,577 | 2,471 | 5,980 | 11,192 | — |
| Inventory | N/A | 1,074 | 1,439 | 2,462 | — |
| Trade Receivables | 873 | 3,323 | 901 | 6,094 | — |
| Trade Payables | 751 | 1,687 | 929 | 4,554 | — |
| Net Working Capital | 489 | 4,405 | -2,792 | 1,501 | — |
| Net Working Capital % of Revenue | 2.9% | 28.2% | -18.0% | 9.8% | — |
| Trade Working Capital | 123 | 2,710 | 1,411 | 4,001 | — |
| Trade Working Capital % of Revenue | 0.7% | 17.4% | 9.1% | 26.2% | — |
| Change in Trade Working Capital | N/A | N/A | N/A | N/A | — |
| Turnover & efficiency | |||||
| Inventory Turnover | N/A | 10.52x | 10.54x | 1.69x | — |
| Days Inventory Outstanding (DIO) | N/A | 34.7 | 34.6 | 216.0 | — |
| Receivables Turnover | 19.16x | 4.69x | 17.25x | 2.50x | — |
| Days Sales Outstanding (DSO) | 19.1 | 77.8 | 21.2 | 145.8 | — |
| Payables Turnover | 4.58x | 6.70x | 16.33x | 0.91x | — |
| Days Payable Outstanding (DPO) | 79.7 | 54.5 | 22.4 | 399.6 | — |
| Cash Conversion Cycle | -60.6 days | 58.0 days | 33.4 days | -37.9 days | — |
| Asset Turnover | 1.68x | 1.37x | 0.35x | 0.46x | — |
| Cash flow & dividends | |||||
| Operating Cash Flow | 3,466 | 1,746 | -584 | -490 | — |
| Free Cash Flow (OCF − Capex proxy) | 1,209 | 1,746 | -798 | 1,691 | — |
| Cash Conversion (OCF / EBITDA) | 161.4% | 123.2% | N/A | N/A | — |
| Dividends Declared | N/A | 0 | 0 | 0 | — |
| Dividend Payout Ratio | N/A | 0.0% | N/A | N/A | — |